NCT03413995 2024-10-16
TRIUMPH
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
Clinical Trials
17 trialsNCT02825628 2024-08-29
CRPC
DexTech Medical AB
Phase 2 Completed
NCT04028388 2024-04-17
ModraDoc006/r vs Docetaxel IV in Metastatic Prostate Cancer
Modra Pharmaceuticals
Phase 2 Completed
NCT03575819 2024-02-01
A Phase 1 Study of FOR46 in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Fortis Therapeutics, Inc.
Phase 1 Completed
NCT03223727 2023-04-18
ROTOR
The Netherlands Cancer Institute
Completed
NCT03434158 2022-11-03
IMANOL
Spanish Oncology Genito-Urinary Group
Phase 2 Completed
NCT02485691 2022-05-27
CARD
Sanofi
Phase 4 Completed
NCT02961257 2022-05-12
CABASTY
Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie
Phase 3 Completed
NCT02814968 2022-04-14
PET/CT and WB MRI for Staging and Response in CRPC Patients Receiving Enzalutamide
The European Uro-Oncology Group
Phase 2 Completed
NCT02815033 2022-04-14
Imaging Staging and Response Prediction in Metastatic Hormono-Sensitive Prostate Cancer Patients Receiving Enzalutamide
The European Uro-Oncology Group
Phase 2 Completed
NCT03646162 2021-12-03
Study of VERU-944 to Ameliorate Hot Flashes in Men With Advanced Prostate Cancer
Veru Inc.
Phase 2 Completed
NCT03024216 2021-05-26
Clinical Study of Atezolizumab (Anti-PD-L1) and Sipuleucel-T in Patients With Asymptomatic or Minimally Symptomatic Metastatic Castrate Resistant Prostate Cancer
University of Hawaii
Phase 1 Completed
NCT02407054 2021-05-11
A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer
Eli Lilly and Company
Phase 2 Completed
NCT01718353 2017-11-20
TAXYNERGY
Sanofi
Phase 2 Completed
NCT02074137 2016-06-02
Evaluation of Safety of Cabazitaxel (Jevtana) in Patients With Metastatic Hormone Refractory Prostate Cancer
Sanofi
Phase 4 Completed
NCT01254279 2015-01-21
Early Access to Cabazitaxel in Patients With Metastatic Hormone Refractory Prostate Cancer Previously Treated With a Docetaxel-containing Regimen
Sanofi
Phase 3 Completed
NCT01595087 2014-11-14
A Phase I/II Study of ODX (Osteodex) in Metastatic Castration Resistant Prostate Cancer (CRPC)
DexTech Medical AB
Phase 1/2 Completed